Clinical Studies

Label‑free spectral imaging to study drug distribution and metabolism in single living cells

February 3, 2021

During drug development, evaluation of drug and its metabolite is an essential process to understand drug activity, stability, toxicity and distribution. Liquid chromatography (LC) coupled with mass spectrometry (MS) has become the standard analytical tool for screening and identifying drug metabolites. Unlike LC/MS approach requiring liquifying the biological samples, we showed that spectral imaging (or spectral microscopy) could provide high‑resolution images of doxorubicin (dox) and its metabolite doxorubicinol (dox’ol) in single living cells. Using this new method, we performed measurements without destroying the biological samples

Read More

Simultaneous analysis of ALK, RET, and ROS1 gene fusions by NanoString in Brazilian lung adenocarcinoma patients

February 3, 2021

Gene fusions have been successfully employed as therapeutic targets for lung adenocarcinoma. However, tissue availability for molecular testing of multiples alterations is frequently unfeasible. We aimed to detect the presence of ALK, RET, and ROS1 rearrangements by a RNA-based single assay in Brazilian lung adenocarcinomas and to associate with clinicopathological features and genetic ancestry.

Read More

Telo GenoTelo Genomics Launches a Commercial Evaluation of Applied Spectral Imaging Automation (AI) with Telo Workflow

October 27, 2020

Commercial Evaluation of Applied Spectral Imaging Automation (AI) with Telo Workflow

Read More

New Webinar from ASI: Quality Assurance and YOU!

July 10, 2019
Read More

The Benefits of Digital Diagnostics Applies to Multi Species As Well

June 5, 2019

About veterinary pathology and how it can benefit from digital diagnostic integrations throughout the laboratory workflow process. Applied Spectral Imaging provides multi-species digital diagnostic solutions in both chromosome analysis such as G-band testing and pathology analysis such as H&E, IHC and FISH testing.

Read More

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7